Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Temozolomide (CCRG 81045: M&B 39831: NSC 362856) is an analogue of mitozolomide displaying similar broad spectrum activity in mouse tumours, but showing considerably less myelosuppression in the toxicology screen. Temozolomide was initially studied intravenously at doses between 50-200 mg m-2 an...

Full description

Bibliographic Details
Main Authors: Newlands, E. S., Blackledge, G. R., Slack, J. A., Rustin, G. J., Smith, D. B., Stuart, N. S., Quarterman, C. P., Hoffman, R., Stevens, M. F., Brampton, M. H.
Format: Online
Language:English
Published: 1992
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977719/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977719/

Similar Items